Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by JDavenporton Dec 13, 2021 11:55am
144 Views
Post# 34225247

RE:As always, nothing going on

RE:As always, nothing going onZwerp, the reason I complained  7 or 8 years ago about the lack of preclinical and clinical activity is that it takes years of scientific work to bring things to fruition, as you call it. Because Boasis has only started this work in a real manner in the last couple of years, we should not have expected too much news up to this point that would be picked up by the extended media. These programs have been going on all along, some things under MTAs that we don't even know about.

It is a measure of your lack of knowledge of the buiness that you are still complaining about the passing of time without accomplishment. Essentially, until 2020, we had no reason to predict when we would see accomplishments begin to appear.

If by the end of 2022 there are still no significant accomplishments then I'll begin to get cranky. As it is, I'm expecting some things to fall this coming year, and I don't mean simple preclinical study results, although these things do and will signal that work has been going on all along.

So, zwerp, you're complaints are the result of a search on your part to be the biggest ah. You accomplished that long ago and because you don't know or understand the business, we can expect you to have no trouble remaining the biggest ah.

jd
<< Previous
Bullboard Posts
Next >>